SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals gets EIR from USFDA for Injectable facility in Gujarat

14 May 2026 Evaluate

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its Injectable facility (F-III) located at Karakhadi, Gujarat on May 13, 2026. 

Earlier, the USFDA had conducted an unannounced cGMP inspection from February 9, 2026 to February 18, 2026. The inspection had been completed with two observations, and none of the observations were related to data integrity. 

Alembic Pharmaceuticals is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

Alembic Pharma Share Price

736.95 1.25 (0.17%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×